EMBARC protocol (550 KB)

ERS 2018 poster (774 KB)

Cross-infection risk in patients with bronchiectasis: (349 KB)

Patient participation in ERS guidelines and research projects (699 KB)

Use of Calgary and microfluidic BioFlux systems (2,126 KB)

iBEST-1 poster (434 KB)

Design of iBest study (718 KB)

Antimicrobial susceptibility of non-fermenting Gram-negative pathogens isolated (724 KB)

Diagnosis and quantification of bronchiectasis using computed tomography or magn (641 KB)

Shopping for phages Unpacking design rules for therapeutic phage cocktails (711 KB)

Biologically Relevant Murine Models of Chronic Pseudomonas aeruginosa Respirator (996 KB)

Bronchiectasis in India results from the European Multicentre Bronchiectasis Aud (1,745 KB)

Criteria and definitions for the radiological and clinical diagnosis of bronchie (261 KB)

Asthma poster (2,621 KB)

Chest Physiotherapy poster (1,828 KB)

Bronchiectasis in Europe data on disease characteristicsfrom the European Bronch (1,690 KB)

Bronchiectasis in Europe data on disease characteristicsfro (1,690 KB)

Multiple breath washout in bronchiectasis.pdf (646 KB)

The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC (437 KB)

Taxonomic position, antibiotic resistance and virulence factors of clinical Achr (954 KB)

Draft genome sequence of the strain 16-537536, isolated from a patient with bron (995 KB)

A systematic review of pharmacotherapeutic clinical trial end-points for bronchi (652 KB)

Cross-infection risk in patients with bronchiectasis a position statement from t (348 KB)

Inhaled aztreonam improves symptoms of cough and sputum production in patients w (379 KB)

Inhaled aztreonam improves symptoms of cough and sputum production in patients w (379 KB)

Validation of the Bronchiectasis Impact Measure (BIM) a novel patient-reported o (519 KB)

Clinical outcomes of bronchiectasis in India data from the EMBARCRespiratory Res (954 KB)

Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients (575 KB)

CONTENT VALIDATION OF THE RESPIRATORY SYMPTOMS SUBSCALE (RSS) OF THE QUALITY OF (258 KB)

Anti-biofilm activity of murepavadin against cystic fibrosis Pseudomonas aerugin (865 KB)

Evaluation of Rapid Polymyxin Pseudomonas test in clinical Pseudomonas aeruginos (327 KB)

Microbial Community Composition in Explanted Cystic Fibrosis and Control Donor L (2,831 KB)

Microbial Community Composition in Explanted Cystic Fibrosis and Control Donor L (2,831 KB)

Whole-genome analysis of Pandoraea species strains from cystic fibrosis patients (1,775 KB)

Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients w (1,833 KB)

Psychometric Validation of the German Translation of the Quality of Life Questio (1,386 KB)

Draft Genome Sequence of a Haemophilus parainfluenzae Strain Isolated from a Pat (116 KB)

Draft Genome Sequence of Haemophilus haemolyticus Strain 16010 O, Isolated from (104 KB)

Participant Identificaitions Centre (1,010 KB)

ALX-009 Respiratory Infections (1,658 KB)

EMBARC Registry (2,952 KB)

iABC Ethical Advisory Board Harry Heijerman (154 KB)

iABC Overview (2,483 KB)

iABC Work Package 2 Marcel Hoppentocht (5,022 KB)

iABC Work Package 2 Maria Diez Aguilar (1,377 KB)

iABC Work Package 2 Miquel Ekkelenkamp (3,687 KB)

iABC Work Package 6 Michael Tunney (156 KB)

Inhaled TIP iBest Study Overview (362 KB)

Murepavadin (406 KB)

Clinical development of QBW251 for use in patients with bronchiectasis (557 KB)

ALX-009-CL-038 Study Synopsis (242 KB)

TBM100/Tobramycin Inhalation Powder Clinical Trial Protocol CTBM100G2202 (1,623 KB)

Clinical Trial Protocol CQBW251C12201 (1,001 KB)

POL7080-201-01 (574 KB)